Antibody Drug Conjugate (ADC) Market to Incur Value Growth at 19% CAGR by 2023. North America to Accrue Maximum Share in ADC Market. According to “Antibody Drug Conjugate (ADC) Industry 2019 Global Market Forecast to 2023 Report” published by Market Research Future. Global Antibody Drug Conjugate Market Analysis By Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies) – Forecast 2023
Antibody Drug Conjugate Market Analysis
The global antibody drug conjugate (ADC) market is projected to witness a stupendous growth at a notable 19% CAGR over the predicted years (2017-2023). ADCs are made of three parts- first a specific antibody for binding, an antigen that has limited expression on the normal cells, second a cytotoxic agent to kill target cancer cells and third a chemical linker to attach the cytotoxic agent to the antibody. This is how antibody drug conjugates work. They are the new age of therapeutic agents. One of the key advantages of antibody drug conjugates is that this will help in bringing together the finest characteristics of both antibodies as well as the chemotherapy’s cytotoxic potential.
There are many factors that is fueling the growth of the antibody drug conjugate market. The different market trends and factors in this market according to an analysis performed by Market Research Future (MRFR) include increasing prevalence of cancer, advancement in medical technology, increased investment in R & D, efficacy of ADC in treating diseases, rising collaboration amid biotechnology and biopharmaceuticals and research institutes, preclinical research, growing geriatric population and rise in obese population. On the contrary, the soaring cost related to the procedure may hamper the growth of the antibody drug conjugate market.
Get Free Sample of Antibody Drug Conjugate Market Report @ https://www.marketresearchfuture.com/sample_request/1113
Key Players Operating in Antibody Drug Conjugate Market
Leading players profiled in the antibody drug conjugate market include Synthon (U.S.), Mersana Therapeutics (U.S.), Oxford BioTherapeutics (U.S.), Heidelberg Pharma (Germany), Progenics Pharmaceuticals (U.S.), Astellas Pharma/Agensys (Japan), Bayer HealthCare (Germany), Agensys, Inc. (U.S.), Concortis Biotherapeutics (U.S.), Genentech (U.S.), AbbVie Inc. (U.S.), Millennium Pharmaceuticals (U.S.), Celldex Therapeutics (U.S.), Pfizer Inc. (U.S.), Immunomedics (U.S.), Antikor (U.K.), Roche Holding AG (Switzerland), ImmunoGen, Inc. (U.S.), and Seattle Genetics (U.S.).
Antibody Drug Conjugate Market Segmentation
As per MRFR report, the global antibody drug conjugate market is segmented on the basis of type, product, technology, application and end-user.
Based on type, it is segmented into drug/toxin, linker, monoclonal antibodies and others. Of these, the antibody drug conjugate linker is expected to have the maximum share in the antibody drug conjugate market.
Based on application, the antibody drug conjugate market is segmented into lymphoma, multiple myeloma, solid tumors, skin cancer, breast cancer, colon cancer, lung cancer, glioblastoma, ovary cancer, pancreas cancer, kidney cancer, prostate cancer and leukemia. Leukemia is further segmented into Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), and Acute Myeloid Leukemia (AML). Of these, breast cancer had the maximum share owing to its increasing prevalence.
Based on product, it is segmented into Kadcyla, Adcertis and others.
Based on technology, the antibody drug conjugate market is segmented into Immunomedics technology, Seattle Genetics technology, ImmunoGen technology and others.
Based on end-user, it is segmented into biopharmaceutical companies, biotechnology companies, academic research institutes, specialized cancer and others.
Antibody Drug Conjugate Market Regional Analysis
Based on region, the antibody drug conjugate market covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America is expected to accrue maximum share in the market due to advancement in manufacturing techniques, technological innovation and contribution of nanotechnology to create ADC. The U.S. FDA has given approval to only three ADC. The antibody drug conjugate market in Europe will have the second largest share followed by the APAC region. APAC is an emerging market and the factors that are driving the growth of the market include increasing government initiatives. A good number of products are under the pipeline and such developments are performed under license agreements.
Antibody Drug Conjugate Industry News/Update
Feb 2019- The Food and Drug Administration (FDA) has granted priority review to ADC (antibody drug conjugate) for diffusing large B-Cell Lymphoma. The chief medical officer of global product development is working with the Food and Drug Administration for bringing this vital novel option to patients having this aggressive ailment as fast as possible. The FDA is most likely to come up with the decision by August 19, 2019.
Jan 2019- Daiichi Sankyo has come up with a late-stage study of ADC to treat patients having low expressing HER2 metastatic/unresectable breast cancer.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
LIST OF TABLES
Table 1 Antibody Drug Conjugate Industry Synopsis, 2017–2023
Table 2 Antibody Drug Conjugate Market Estimates & Forecast, 2017–2023, (USD Million)
Table 3 Antibody Drug Conjugate Market, By Region, 2017–2023, (USD Million)
Table 4 Antibody Drug Conjugate Market, By Type, 2017–2023, (USD Million)
Table 5 Antibody Drug Conjugate Market, By Application, 2017–2023, (USD Million)
Table 6 Antibody Drug Conjugate Market, By Product, 2017–2023, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation For Antibody Drug Conjugate Market
Figure 3 Segmentation Market Dynamics For Antibody Drug Conjugate Market
Figure 4 Global Antibody Drug Conjugate Market Share, By Type, 2016
Figure 5 Global Antibody Drug Conjugate Market Share, By Application, 2016
Figure 6 Global Antibody Drug Conjugate Market Share, By Product, 2016
Browse Complete Premium Research Report Enabled with Detailed TOC @ https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
+1 646 845 9312